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Background: Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (pfDHFR-TS) is a well-defined
target of anti-malarial drug, such as pyrimethamine and cycloguanil. Emergence of malaria parasites resistant to
these drugs has been shown to be associated with point mutations of the gene coding for the target enzymes.
Although the 3D-structure of P. falciparum bifunctional pfDHFR-TS has been reported previously, relatively little is
known about the interactions between the pfDHFR and pfTS domains and the roles of the junctional region that
links the two domains together. Therefore, a thorough understanding of the interaction of the two domains and
the role of the junctional region of this target is important as the knowledge could assist the development of new
effective anti-malarial drugs aimed at overcoming drug-resistant malaria.
Methods: A system was developed to investigate the interaction between pfDHFR and pfTS domains and the role
of the junctional region on the activity of the recombinant pfTS. Based on the ability of co-transformed plasmids
coding for pfDHFR and pfTS with truncated junctional region to complement the growth of TS-deficient Escherichia
coli strain χ2913recA(DE3) on minimum media without thymidine supplementation, active pfTS mutants with
minimal length of junctional region were identified. Interactions between active pfDHFR and the pfTS domains
were demonstrated by using a bacterial two-hybrid system.
Results: Using TS-deficient E. coli strain χ2913recA(DE3), the authors have shown for the first time that in
P. falciparum a junctional region of at least 44 amino acids or longer was necessary for the pfTS domain to be
active for the synthesis of thymidylate for the cells. Truncation of the junctional region of the bifunctional
pfDHFR-TS further confirmed the above results, and suggested that a critical length of the junctional peptide of
pfDHFR-TS would be essential for the activity of TS to catalyze the synthesis of thymidylate.
Conclusion: The present study demonstrated the interactions between the pfDHFR and pfTS domains of the
bifunctional pfDHFR-TS, and revealed that the junctional region linking the two protein domains is essential for the
expression of catalytically active pfTS domain. The findings could be useful since inhibition of the pfDHFR-TS
domain-domain interaction could form a basis for the development of new anti-malarial drugs based on targeting
the non-active site region of this important enzyme.
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Malaria remains an important disease in many tropical and
sub-tropical countries [1]. The disease has become a global
health threat, with over one million deaths annually, mostly
children in sub-Saharan Africa [2]. The emergence of mal-
aria resistance to almost all the currently available anti-
malarial drugs has highlighted an urgent need to identify
new malarial targets, and develop new effective drugs to
combat the drug-resistant parasites [3-8]. Plasmodium
falciparum dihydrofolate reductase-thymidylate synthase
(pfDHFR-TS) is a well-defined target of antifolate drugs
such as pyrimethamine and cycloquanil. The enzyme is
responsible for the production of folates as well as
thymidylate (dTMP) required for DNA synthesis [9]. Un-
fortunately, the emergence of anti-folate resistance has
compromised the utility of the drugs and presented an ur-
gent need to discover new drug targets and to develop
novel effective drugs to combat drug-resistant parasites.
Structural studies of P. falciparum DHFR-TS revealed
that the native enzyme is a homodimeric protein com-
prising 231 residues of DHFR domain (~27 kDa) at the
N-terminus, followed by a short junctional region of 89
residues (~11 kDa) and 288 residues (~34 kDa) of the
TS domain at the C-terminus of the protein [10,11]. It
has been postulated that such a bifunctional arrange-
ment could have evolved as a mechanism for the tight
coupling generation of reduced folates required for the
synthesis of amino acids, purine, pyrimidine, and dTMP,
a phenomenon called “substrate channelling”. Support for
this hypothesis comes from the evidence of metabolic
channelling of the H2folate produced in the TS-catalyzed
reaction, which was found to proceed at a faster rate than
the diffusion rate [12]. Data from the bifunctional DHFR-
TS of Leishmania major and Toxoplasma gondii also
supported the substrate channelling hypothesis [12,13].
Nevertheless, the mechanism of substrate channelling for
pfDHFR-TS remains unclear since, based on the structure
of pfDHFR-TS, such a mechanism could not explain the
delivery of H2folate from the pfTS domain to the active site
of pfDHFR, and an electrostatic channelling mechanism
was proposed as a possible alternative method [14-16].
The junctional region (JR) linked between the DHFR
and TS domains in parasitic protozoa reported thus far
varies significantly in length depending upon the source
[9,10,16,17]. The long JR found in P. falciparum (89 amino
acids) provides a number of interactions which facilitate
contacts with the DHFR domain of the opposite half of
the DHFR-TS dimer, and brings the two DHFR domains
closer together. Structural alignments of DHFR-TS en-
zymes from Cryptosporidium hominis and P. falciparum
revealed that the JR played an important role in the orien-
tation of the DHFR domain relative to TS [17]. Therefore,
inhibition of the interaction between the JR, the DHFR
and TS domains could be a possible approach for thedevelopment of novel effective anti-malarial drugs [18].
The present study therefore describes an approach to-
wards understanding the interactions between DHFR and
TS domains of the bifunctional pfDHFR-TS, and the im-
portant role of JR on the activity of the TS domain. This is
the first successful expression of the catalytically active
pfTS domain that has JR attached at its N-terminus, as all
attempts in the past to express pfTS domain failed.
Through deletion of the JR, it is demonstrated that a crit-
ical length of JR is required for proper folding of the pfTS
domain leading to an active molecule of pfTS. The find-
ings highlight the importance of the JR which links DHFR
and TS domains and suggest a possible alternative in
exploiting the non-active site region of this important en-




Restriction endonucleases and T4 DNA ligase were
obtained from New England Biolabs, Life Technology, Inc.
20-deoxyuridylate, 5-fluoro-20- deoxyuridylate, and NADPH
were from Sigma. MTX-sepharose CL-6B (~ 1 μmole/ml)
[12], H2folate [19], and CH2H4folate [20] were prepared as
described. Custom primer syntheses and DNA sequencing
were from BioDesign Co Ltd and Genome Institute. TS-
deficient Escherichia coli strain χ2913recA(DE3) was used
for the genetic complementation studies to monitor the
function of TS.
Construction and transformation of recombinant plasmids
The gene coding for P. falciparum DHFR (amino acids 1–
228) was amplified using a template DNA from
pETpfDHFR-TS [21]. The pfJRTS mutants were constructed
by the PCR mutagenesis method. The PCR reaction
(100 μl) is composed of 50 ng pETpfDHFR-TS as a DNA
template, 25 ρmole of each primer (Table 1), 200 μM of
dNTPs, 1.5 mMMgCl2, and 2.5 units of Taq DNA polymer-
ase in 1 x reaction buffer. The PCR conditions were as fol-
lows: 1 cycle of 94°C for 3 min, then 25 cycles of 94°C for
45 sec, annealing at 45°C for 30 sec, and extension at 72°C
for 1 min. This was followed by a final extension at 72°C for
5 min. Deletion mutants of bifunctional pfDHFR-TS were
constructed using the whole plasmid amplification PCR ap-
proach [22] employing recombinant plasmid pET15b carry-
ing the P. falciparum DHFR-TS(3D7) gene as a template
and sets of primers as shown in Table 2. The PCR products
were analysed by agarose electrophoresis, and were further
purified using a Qiaquick Gel Extraction kit.
The amplified product was cloned into pAC28 ex-
pression plasmid [23] to express catalytically active
pACpfDHFR. Likewise, sequences coding for truncated
JR with the pfTS domain attached were amplified using
the primers as listed in Table 1, and cloned into pET-15b
Table 1 Primers used for the construction of truncated pfJRTS mutants
Name Length
(bases)
Sequence (5′⟶ 3′) Utilities and description
JRTSΔ232-235 28 AAAGAATCCCATGGAACAAAATTGTATA Sense strand PCR primer for the construction of pET-pfJRTSΔ232-235.
Bold-face letters represent Met introduced in front of Glu236.
Underlined sequence is the restriction site for NcoI.
JRTSΔ232-251 28 AAAGAATCCCATGGAAAAGAATGATGAC Sense strand PCR primer for the construction of pET-pfJRTSΔ232-251.
Bold-face letters represent Met-Glu introduced infront of Lys252.
Underlined sequence is the restriction site for NcoI.
JRTSΔ232-265 28 AAAGAATCCCATGGAATTTTACAAAAAT Sense strand PCR primer for the construction of pET-pfJRTSΔ232-265.
Bold-face letters represent Met introduced in front of Glu266. Underlined
sequence is the restriction site for NcoI.
JRTSΔ232-271 28 AAAGAATCCCATGGACAAATATAAAATT Sense strand PCR primer for the construction of pET-pfJRTSΔ232-271.
Bold-face letters represent Met introduced in front of Asp272. Underlined
sequence is the restriction site for NcoI
JRTSΔ232-274 57 CCCCTCTAGAAATAATTTTGTTTAACTTTAA
GAAGGAGATATACCATGAAAATTAAT
Sense strand PCR primer for theconstruction of pET-pfJRTSΔ232-274.
Bold-face letters represent Met introduced in front of Lys275. Underlined
sequence is the restriction site for XbaI
JRTSΔ232-276 57 CCCCTCTAGAAATAATTTTGTTTAACTTTAAGAA
GGAGATATACCATGAATTATGAA
Sense strand PCR primer for the construction of pET-pfJRTSΔ232-276.
Bold-face letters represent Met introduced in front of Asn277. Underlined
sequence is the restriction site for XbaI
JRTSΔ232-277 57 CCCCTCTAGAAATAATTTTGTTTAACTTTAA
GAAGGAGATATACCATGTATGAAAAT
Sense strand PCR primer to prepare construct pET-pfJRTSΔ232-277.
Bold-face letters represent Met introduced in front of Tyr278. Underlined
sequence is the restriction site for XbaI
JRTSΔ232-299 28 AAAGAATCCCATGGAAGAGAAAAATAAA Sense strand PCR primer to prepare construct pET-pfJRTSΔ232-299.
Bold-face letters represent Met introduced in front of Glu300. Underlined
sequence is the restriction site for NcoI
N3TS 22 ACTCATGGATCCTTAAGCAGCC Antisense strand PCR primer for the construction of all pET-pfJRTS
mutants. Underlined sequence is the restriction site for BamHI
Table 2 Primers used for construction of truncated bifunctional pfDHFR-TS
Name Length
(bases)
Sequence (5′⟶ 3′) Utilities and description
Δ229-277 Sense 60 ACAACATTGGATTTTATCATTTATAAGAAATAT
GAAAATGATGATGATGATGAAGAAGAA
Sense strand PCR primer for the construction of pfDHFR-TSΔ229-
277. Lys228 (italic) was followed by Tyr278(bold)
Δ229-277 Antisense 60 TTCTTCTTCATCATCATCATCATTTTCATATTTC
TTATAAATGATAAAATCCAATGTTGT
Antisense strand PCR primer for the construction of pfDHFR-
TSΔ229-277
Δ229-276 Sense 60 ACAACATTGGATTTTATCATTTATAAGAAAAAT
TATGAAAATGATGATGATGATGAAGAA
Sense strand PCR primer for the construction of pfDHFR-TSΔ229-
276. Lys228 (italic) was followed by Asn277(bold)
Δ229-276 Antisense 60 TTCTTCATCATCATCATCATTTTCATAATTTTTC
TTATAAATGATAAAATCCAATGTTGT
Antisense strand PCR primer to amplify pfDHFR-TSΔ229-276
Δ229-275 Sense 60 ACAACATTGGATTTTATCATTTATAAGAAA
ATTAATTATGAAAATGATGATGATGATGAA
Sense strand PCR primer for the construction of pfDHFR-TSΔ229-
275. Lys228 (italic) was followed by Ile276(bold)
Δ229-275 Antisense 60 TTCATCATCATCATCATTTTCATAATTAATTTTC
TTATAAATGATAAAATCCAATGTTGT
Antisense strand PCR primer to amplify pfDHFR-TSΔ229-275
Δ229-274 Sense 60 ACAACATTGGATTTTATCATTTATAAGAAAAAA
ATTAATTATGAAAATGATGATGATGAT
Sense strand PCR primer for the construction of pfDHFR-TSΔ229-
274. Lys228 (italic) was followed by Lys275(bold)
Δ229-274 Antisense 60 ATCATCATCATCATTTTCATAATTAATTTTTTTCT
TATAAATGATAAAATCCAATGTTGT
Antisense strand PCR primer to amplify pfDHFR-TSΔ229-274
Δ229-271 Sense 60 ACAACATTGGATTTTATCATTTATAAGAAAGAC
AAATATAAAATTAATTATGAAAATGAT
Sense strand PCR primer for the construction of pfDHFR-TSΔ229-
271. Lys228 (italic) was followed by Asp272(bold)
Δ229-271 Antisense 60 ATCATTTTCATAATTAATTTTATATTTGTCTTTCTT
ATAAATGATAAAATCCAATGTTGT
Antisense strand PCR primer to amplify pfDHFR-TSΔ229-271
Δ229-265 Sense 60 ACAACATTGGATTTTATCATTTATAAGAAAGAA
TTTTACAAAAATGTAGACAAATATAAA
Sense strand PCR primer for the construction of pfDHFR-TSΔ229-
265. Lys228 (italic) was followed by Glu266(bold)
Δ229-265 Antisense 60 TTTATATTTGTCTACATTTTTGTAAAATTCTTTCT
TATAAATGATAAAATCCAATGTTGT
Antisense strand PCR primer to amplify pfDHFR-TSΔ229-265
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251, pET-pfJRTS△232-265, pET-pfJRTS△232-271, pET-
pfJRTS△232-274, pET-pfJRTS△232-276, pET-pfJRTS△
232-277, and pET-pfJRTS△232-299. These mutant pET-
pfJRTS plasmids were transformed into electro-competent
E. coli strain χ2913 cells by electroporation using pulses
set at 1.8 kV, 400Ω, 25 μF and a pulse length of ~8-
10 min. After centrifugation at 6,500 g at 4°C for 10 min
and resuspending the cell pellets in 2 ml of 10% glycerol, a
second electroporation was performed to transform 100 μl
of the first transformed cells with ~50 ng of pAC-pfDHFR.
After recovering the cells by addition of 0.9 ml of LB
broth followed by vigorous shaking for 1 hour at 37°C,
the cells were plated onto LB agar containing 100 μg/ml
ampicillin and 30 μg/ml kanamycin. Colonies appeared
on the plates after overnight incubation at 37°C were in-
dividually picked and grown overnight in 1 ml LB broth
containing 100 μg/ml ampicillin and 30 μg/ml kanamycin
at 37°C.
Truncation of JR of the bifunctional pfDHFR-TS was
performed by PCR amplification using the whole recom-
binant plasmid pET15b carrying gene coding for the bi-
functional P. falciparum DHFR-TS (3D7) as a template,
and the primers as listed in Table 2. The resulting truncated
mutants, i.e., pfDHFR-TSΔ229-265, pfDHFR-TSΔ229-271,
pfDHFR-TSΔ229-274, pfDHFR-TSΔ229-275, pfDHFR-
TSΔ229-276, and pfDHFR-TSΔ229-277, were used to co-
transform pAC-28 plasmid in the complementation study.
Genetic complementation studies
Overnight culture of the co-transformants was streaked
on a minimal agar plate [24] containing 100 μg/ml ampi-
cillin, 30 μg/ml kanamycin, and 0.025 mM IPTG without
thymidine supplementation. The plates were incubated
at 37°C for 48 hours. Colonies appearing on this plate
were considered to have positive genetic complementa-
tion, and were selected for subsequent characterization
and verification of the expressed enzymes.
Expression and purification of the expressed enzymes
An overnight culture of E. coli χ2913 harbouring two
plasmids, i.e., pAC-pfDHFR and truncated pET-pfJRTS
with different lengths of truncated JR, was inoculated at
1% inoculum in LB containing 100 μg/ml of ampicillin,
30 μg/ml kanamycin. The bacteria were grown at 37°C
until the OD600 of the cell suspension reached ~0.5-0.6,
and isopropyl β-D thiogalactopyranoside (IPTG) was
added at a final concentration of 0.025 mM. The culture
was allowed to grow with shaking at 20°C for 20 hours.
The cells were harvested by centrifugation at 6,500 g for
10 min at 4°C, washed once with 250 ml cold phosphate
buffered saline, pH 7.4, resuspended in buffer A (20 mM
potassium phosphate buffer, pH 7.0, 0.1 mM EDTA,
10 mM DTT, 20% glycerol) containing 0.2 M KCl, andpassed through a French Pressure Cell (American In-
struments Co Inc, USA) at 12,000 psi three times. After
centrifugation at 20,000 g for 1 hour at 4°C, the clear
supernatant of the crude sample was circulated at a flow
rate of ~0.5 ml/min in a methotrexate-sepharose CL-6B
column (1.5 × 5.0 cm) pre-equilibrated with buffer A
containing 0.2 M KCl. After overnight circulation, the
column was washed with 30 ml of buffer A containing
0.75 M KCl, followed by 20 ml of buffer A containing
0.2 M KCl. The column was then washed with 30 ml of
elution buffer (50 mM TES pH 7.8, 0.1 mM EDTA,
10 mM DTT, 20% glycerol, 50 mM KCl) containing 4 mM
H2folate to elute DHFR. Fractions of 1 ml were collected.
Active fractions with DHFR activity were pooled, concen-
trated, and H2folate in the pooled fraction was removed by
passing the pooled fraction through a pre-packed NAP-25
column (Pharmacia) pre-equilibrated with buffer A.
Enzyme assays and protein analysis
The activity of DHFR was determined spectrophotomet-
rically by monitoring the rate of decrease in absorbance
at 340 nm [12,25]. The standard DHFR assay (1 ml) in a
1-cm path-length cuvette was composed of 100 μM
H2folate, 100 μM NADPH, 50 mM TES, pH 7.0, 75 mM
β-mercaptoethanol, 1 mg/ml bovine serum albumin, and
~0.01 units of enzyme. The reaction was initiated with
H2folate. One unit of DHFR activity is defined as the
amount of enzyme that produces 1 μmole of product
per minute at 25°C.
The activity of TS was determined by monitoring the in-
crease of absorbance at 340 nm due to the formation of
H2folate at 25°C [26]. The reaction (1 ml) in 1-cm path-
length cuvette was composed of 50 mM TES, pH 7.4,
25 mM MgCl2, 1 mM EDTA, 6.5 mM HCHO, 75 mM β-
mercaptoethanol, 100 μM (6R) CH2H4folate, 125 μM
dUMP and the enzyme. The reaction components, except
for dUMP, were incubated at 25°C for at least 5 min to ob-
tain the baseline prior to initiation the reaction with
dUMP. One unit of TS activity is defined as the amount of
enzyme that produces 1 nmole of product per minute at
25°C. The activities of the expressed enzymes were reported
as mean ± standard deviation.
[3H]-FdUMP binding assay
The ability of the pfJRTS mutants with truncated JR to
form covalent complex with [3H]-FdUMP and CH2H4folate
was investigated by incubating the mutant proteins with
0.5 μM [3H]-FdUMP (19.3 Ci/mmol), 0.1 mM CH2H4folate,
and 6.5 mM formaldehyde in 50 mM TES pH 7.4, 25 mM
MgCl2, 1 mM EDTA, and 75 mM β-mercaptoethanol for
15 min at room temperature. The reaction was then
electrophoresed on 12.5% SDS-PAGE. After Coomassie-
Blue staining and destaining, the gel was soaked with auto-
radiography enhancer (EN3HANCE™, New England
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temperature. This was followed by washing the gel with cold
water and drying the gel on a piece of filter paper under
vacuum at 80°C for 30 min. The dried gel was then exposed
on AGFA X-ray film at −80°C with intensifying screens for
three to five days before development of the X-ray film.
Bacterial two-hybrid system
Interactions between pfDHFR domain and pfTS domain
including those pfTS mutants with truncated JR were in-
vestigated using an E. coli two-hybrid system (Stratagene
Inc) [27,28]. The sequence coding for pfDHFR domain
was cloned into pBT (bait) vector to yield pBT-pfDHFR,
whereas the pfJRTS was cloned into pTRG (target) vec-
tor to yield the pTRG-pfJRTS plasmid. The two plasmids
were co-transformed into BacterioMatch two-hybrid sys-
tem reporter strain E. coli XL1-blue MRF’. Positive inter-
action is indicated by the ability of the bacteria to grow on
LB agar plate supplemented with 250 μg/ml carbenicillin, 15
μg/ml tetracycline, 34 μg/ml chloramphenical, and 50 μg/
ml kanamycin (LB-CTCK).
Results
Construction of pfJRTS and pfDHFR-TS mutants and
growth complementation studies
Unlike the DHFR domain of the bifunctional pfDHFR-TS,
which can be heterologously expressed to yield the catalyt-
ically active form of enzyme [29-32], all attempts to ex-
press the catalytically active domain of pfTS have failed.
Evidence from deletion of pfDHFR-TS suggested that the
amino terminus of the pfDHFR domain is important for
the function of the pfTS domain, and interactions between
the pfDHFR and pfTS domains are important [18]. To ad-
dress the important function of JR, mutant constructs of
the pfJRTS domain with various lengths of JR sequences
were constructed and co-transformed with plasmid ex-
pressing the catalytically active pfDHFR domain (pAC-
pfDHFR) in TS-deficient E. coli strain χ2913recA(DE3).
Successful expression of catalytically active pfTS was moni-
tored by the ability of the co-transformed bacteria to com-
plement growth upon plating on minimum agar plate and
the detectable TS activity in the crude extract of the cells.
Figure 1 illustrates the constructs of pfJRTS mutants
containing varying lengths of JR attached to the C-
terminus of the pfDHFR domain (Asn231). The mutant
with the longest JR (pET-pfJRTS△232-235) had only
four amino acids of the JR (Lys232-Asn235) deleted, while
mutants with the shortest JR (pET-pfJRTS△232-299)
had 68 residues (Lys232-Lys299) removed. A similar
approach was undertaken to construct bifunctional
pfDHFR-TS deletion mutants of which the JR sequence
was shortened to compare the effects of JR deletion with
the truncated mutants of pfJRTS constructs. The bifunc-
tional pfDHFR-TS deletion mutants being constructedinclude pET-pfDHFR-TS△229-265, pET-pfDHFR-TS△
229-271, pET-pfDHFR-TS△229-274, pET-pfDHFR-
TS△229-275, pET-pfDHFR-TS△229-276, and pET-
pfDHFR-TS△229-277 (Figure 2). Figure 3 shows the 89
amino acids of P. falciparum JR sequence and indicates
the positions of amino acids that were chosen to prepare
truncated and deletion mutants. Results from growth
complementation monitored after incubation of the plates
overnight at 37°C revealed that pET-pfJRTS△232-235,
pET-pfJRTS△232-251, pET-pfJRTS△232-265, pET-pfJRTS△
232-271, pET-pfJRTS△232-274, and pET-pfJRTS△232-
276 with corresponding JR length of 85, 69, 55, 49, 46, 44
amino acid residues, respectively, could grow on mi-
nimum media (Figure 4A, lanes 2–7), while pET-
pfJRTS△232-277 and pET-pfJRTS△232-299 which had
the JR length of 43 and 21 residues, respectively, did not
show growth complementation (Figure 4A, lanes 8–9).
The results suggest that the length of JR was important for
the proper folding of the TS domain and hence affected its
function. The data revealed that at least 44 residues (the
mutant pET-pfJRTS△232-276) were required in the case of
JR of P. falciparum in order for the pfTS domain to func-
tion properly.
As with the result for the construct pfJRTS TSΔ229-277,
TS-deficient E. coli strain χ2913 recA(DE3) transformed
with pET-pfDHFR-TS△229-277and pAC-28 could not
grow on a minimum agar plate (Figure 4B, lane 7). There-
fore, pfDHFR-TS mutants with a longer JR sequence, i.e.
pET-pfDHFR-TS△229-265, pET-pfDHFR-TS△229-271,
pET-pfDHFR-TS△229-274, pET-pfDHFR-TS△229-275,
and pET-pfDHFR-TS△229-276, were constructed and
tested for growth complementation. Complementation
studies revealed that the constructs pET-pfDHFR-TS△229-
265, pET-pfDHFR-TS△229-271, and pET-pfDHFR-TS△229-
274 were able to grow on both LB agar and minimum agar
supplemented with 0.025 mM IPTG (Figure 4B, lanes 2–4),
whereas the construct pET-pfDHFR-TS△229-275 and
pET-pfDHFR-TS△229-276 failed to show complementa-
tion (Figure 4B, lanes 5–6). The results using deletion mu-
tants of bifunctional pfDHFR-TS are in good agreement
with those from co-transformation of plasmids encoding
pfJRTS with varying lengths of JR and plasmid expressing
catalytically active pfDHFR.
[3H]-FdUMP binding studies of pfJRTS and pfDHFR-TS
mutant constructs expressing pfTS
[3H]-FdUMP binding studies were carried out to monitor
the expression of catalytically active pfTS from truncated
pfJRTS mutants and the pfDHFR-TS deletion mutants
found to show growth complementation on minimum
media. Crude extracts from E. coli χ2913 co-transformed
with plasmid expressing pfDHFR and mutant pfJRTSs
with varying length of JR were subjected to SDS-PAGE
(Figure 5A(I) and B(I)) and the gel was exposed to X-ray
Figure 1 Schematic diagram representing full-length pfDHFR-TS, pfDHFR domain, and pfTS domains with truncated junction region
(JR). Gene encoding amino acid residues 1–228 of pfDHFR domain was cloned into pAC28 expression vector, whereas gene fragments encoding
the pfTS domain with different lengths of JR that are attached to the N-terminus (amino acid residue 320) of pfTS were cloned into the pET15b
expression vector. The numbers of amino acid are shown above the gene and the names of the mutants are indicated at the right.
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results from genetic complementation results, co-
transformation of pAC-pfDHFR and pET-pfJRTS△
232-235, pET-pfJRTS△232-251, pET-pfJRTS△232-265,
pET-pfJRTS△232-271, pET-pfJRTS△232-274 and pET-
pfJRTS△232-276 formed [3H]-FdUMP-enzyme complexes
which could be visualized on X-ray film as a band according
to the size predicted from that of pfJRTS (Figure 5B, lanes
2–7). Co-transformation of pAC-pfDHFR and pfJRTS△232-
277 and pfJRTS△232-299, however, showed relatively weak
signal from [3H]-FdUMP-enzyme complexes (Figure 5B,
lanes 8–9).
To investigate the role of JR in bifunctional pfDHFR-TS,
formation of [3H]-FdUMP-enzyme complexes were moni-
tored from the extracts of E. coli cells co-transformed
with pAC28 plasmid and pET-pfDHFR-TS△229-265,Figure 2 Schematic diagram representing full-length and truncated p
1–228 followed by truncated JR sequences of different lengths linked to th
expression vector. The numbers of amino acid are shown above the genepET-pfDHFR-TS△229-271, pET-pfDHFR-TS△229-274,
pET-pfDHFR-TS△229-275, and pET-pfDHFR-TS△229-
276 (Figure 5C and 5D). The results showed that both
crude extracts and partially purified proteins of these
constructs could form complexes with [3H]-FdUMP,
though growth complementation could not be observed
from pET-pfDHFR-TS△229-275, pET-pfDHFR-TS△229-
276, and pET-pfDHFR-TS△229-277 (Figure 5D, lanes 5–7).
Purification and characterization of the expressed enzymes
Crude extracts of the transformed TS-deficient E. coli
that were both positive and negative from the growth
complementation studies were assayed for DHFR and
TS activities. Extracts that were positive were passed
through a MTX-affinity column for purification of the
pfDHFR domain [32]. The results from enzyme assaysfDHFR-TS. Constructs of pfDHFR domain containing amino acids
e N-terminus of the pfTS domain were cloned into the pET15b
and the names of the mutants are indicated.
Figure 3 Full-length sequence of Plasmodium falciparum JR and the sequences of truncated pfJRTS mutants. The 89 amino acids of the
full-length sequence of P. falciparum JR are shown, with amino acid numbers in relation to the full-length bifunctional pfDHFR-TS indicated above
the sequence. Arrows indicate the amino acids corresponding to the first amino acid of the truncated pfJRTS constructs. The region where the
α-helix is located is marked in the box.
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http://www.malariajournal.com/content/12/1/91revealed that the specific activity of pfDHFR from all the
co-transformants were not significantly different among
the crude extracts (average 36.2 ± 3.1 nmole/min/mg), but
the activity was only about half of that observed from the
crude extract of the bifunctional pfDHFR-TS (Table 3).Figure 4 Growth complementation of TS-deficient Escherichia coli cel
containing truncated JR. (B) pAC28 co-transformed with pET-pfDHFR-TS wi
Bertani (LB), minimum media (MM), and minimum media supplemented w
controlled plasmid.The specific activities of the partially purified pfDHFR
upon affinity purification were 1,371 ± 208 nmole/min/mg
(Table 3), about 3 times lower than that obtained from the
purified pfDHFR-TS. Interestingly, the TS activities of the
purified enzymes from the truncated pfJRTS mutants arels harbouring. (A) pAC-pfDHFR co-transformed with pET-pfJRTS
th truncated JR. Cells from overnight culture were streaked on Luria-
ith 0.025 mM IPTG (MM + IPTG). pET-pfDHFR-TS (3D7) was used as a
Figure 5 [3H]-FdUMP binding of crude extracts and partially purified proteins. Crude extracts and partially purified proteins from plasmids
encoding pfDHFR co-transformed with pfJRTS mutants with truncated JR (panels A and B, respectively), and plasmids encoding pAC28 co-transformed
with pfDHFR-TS with truncated JR (panel C and D, respectively) were labeled with [3H]-FdUMP. For panels A and B: lane 1, pfDHFR-TS (3D7); lane 2,
pfJRTS△232-235 co-expressed with pAC28-pfDHFR; lane 3, pfJRTS△232-251 co-expressed with pAC28-pfDHFR; lane 4, pfJRTS△232-265 co-expressed with
pAC28-pfDHFR; lane 5, pfJRTS△232-271 co-expressed with pAC28-pfDHFR; lane 6, pfJRTS△232-274co-expressed with pAC28-pfDHFR; lane 7, pfJRTS△232-
276 co-expressed with pAC28-pfDHFR; lane 8, pfJRTS△232-277 co-expressed with pAC28-pfDHFR; lane 9, pfJRTS△232-299 co-expressed with pAC28-
pfDHFR. For panels C and D: lane 1, pfDHFR-TS (3D7); lane 2, pfDHFR-TS△229-265; lane 3, pfDHFR-TS△229-271; lane 4, pfDHFR-TS△229-274; lane 5,
pfDHFR-TS△229-275; lane 6, pfDHFR-TS△229-276; lane 7, pfDHFR-TS△229-277993. M is the molecular weight standard markers. (I) Coomassie blue
stained SDS-PAGE, (II) autoradiogram of the SDS gel.
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http://www.malariajournal.com/content/12/1/91in most cases 1–2 times higher than that from the purified
pfDHFR-TS. The activity of pfTS was found to co-elute
with that of pfDHFR, suggesting that the expressed pfTS
domain was somehow associated with the pfDHFR do-
main. As indicated in Table 3, the TS activity of the pfJRTS
mutants was found to decrease upon shortening the
length of JR in the construct.
The importance of the length of the JR sequence on the
activity of pfTS was also investigated using the bifunctionalpfDHFR-TS. Site-directed mutagenesis of the bifunctional
pfDHFR-TS was performed to yield mutants containing the
same lengths of JR as for the pfJRTS mutant constructs
described above. These mutants include pET-pfDHFR-
TS△229-265, pET-pfDHFR-TS△229-271, pET-pfDHFR-TS△
229-274, pET-pfDHFR-TS△229-275, pET-pfDHFR-TS△229-
276, and pET-pfDHFR-TS△229-277. Table 4 summarizes
the pfDHFR and pfTS activities of the bifunctional DHFR-
TS and the bifunctional mutants from the crude extracts
Table 3 DHFR and TS activities in crude extracts and purified enzymes from TS-deficient Escherichia coli χ2913
harbouring pAC-pfDHFR and pET-pfJRTS with different lengths of JR
Specific activity
Plasmid Crude extract* Purified enzyme**
(nmole/min/mg) (nmole/min/mg)
DHFR TS DHFR TS
1. pET-pfDHFRTS (3D7) 70.3 ± 3.6 3.7 ± 0.4 5331.9 ± 113.8 99.0 ± 1.0
2. pAC-pfDHFR + pET-pfJRTSΔ232-235 39.5 ± 5.8 2.6 ± 0.2 1511.1 ± 227.5 164.1 ± 22.6
3. pAC-pfDHFR + pET-pfJRTSΔ232-251 34.2 ± 5.8 2.1 ± 0.4 1394.5 ± 275.7 134.4 ± 8.9
4. pAC-pfDHFR + pET-pfJRTSΔ232-265 37.8 ± 5.3 3.8 ± 0.5 1668.4 ± 234.7 132.0 ± 7.4
5. pAC-pfDHFR + pET-pfJRTSΔ232-271 39.9 ± 7.3 3.9 ± 0.7 1601.7 ± 206.1 107.9 ± 23.3
6. pAC-pfDHFR + pET-pfJRTSΔ232-274 38.3 ± 5.6 1.5 ± 0.3 1328.8 ± 231.7 70.1 ± 0.2
7. pAC-pfDHFR + pET-pfJRTSΔ232-276 34.2 ± 9.1 1.1 ± 0.1 1140.1 ± 137.8 44.2 ± 7.5
8. pAC-pfDHFR + pET-pfJRTSΔ232-277 31.0 ± 8.1 ND 1136.5 ± 132.0 ND
9. pAC-pfDHFR + pETpfJRTSΔ232-279 34.9 ± 7.2 ND 1193.6 ± 111.8 ND
10. pAC-28 + pET-15b 7.7 ± 0.4 ND - -
* Average values from three independent experiments.
**Average values from two independent experiments.
ND: not detectable.
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growth complementation experiments, no pfTS activity
was detected from the crude extracts and partial purifica-
tion of pET-pfDHFR-TS△229-275, pET-pfDHFR-TS△229-
276, and pET-pfDHFR-TS△229-277 mutants. However,
the activities of the pfDHFR domain of these mutants
remained active, though they were found to gradually
decrease upon shortening the length of the JR sequence.
Demonstration of pfDHFR-TS domain-domain interaction
by Escherichia coli two-hybrid system
The interaction between the pfDHFR domain and
pfJRTS was demonstrated using E. coli BacterioMatch™Table 4 DHFR and TS activities in crude extracts and purified





1. pET-pfDHFR-TS (3D7) 70.3 ± 3.6
2. pET-pfDHFR-TSΔ229-265 64.7 ± 5.8
3. pET-pfDHFR-TSΔ229-271 75.5 ± 12.4
4. pET-pfDHFR-TSΔ229-274 74.4 ± 18.5
5. pET-pfDHFR-TSΔ229-275 66.7 ± 7.3
6. pET-pfDHFR-TSΔ229-276 83.9 ± 1.0
7. pET-pfDHFR-TSΔ229-277 82.1 ± 3.0
8. pET-15b 3.1 ± 0.1
* Average values from three independent experiments.
** Average values from two independent experiments.
ND: not detectable.two-hybrid system (Strategene). The pfDHFR domain
was cloned into NotI-BamHI sites of a pBT bait plasmid,
resulting in a pBT-pfDHFR plasmid, which contains the
pfdhfr gene fused at the end of the bacteriophage λcI
gene. The pfJRTS domain was cloned into BamHI-XhoI
sites of the pTRG target plasmid, resulting in constructs
that express truncated pfJRTS domains fused with the α-
subunit of RNA polymerase. If the pfJRTS domain could
interact with the pfDHFR domain, then this would
stabilize the binding of RNA polymerase located close to
the promoter and activate the transcription of the AmpR
reporter gene. As a consequence, the transformed
reporter strain (E. coli XL1-blue MRF’) showed growthenzymes from TS-deficient Escherichia coli χ2913





3.7 ± 0.4 5331.9 ± 113.8 99.0 ± 1.0
1.1 ± 0.3 4583.2 ± 228.9 44.8 ± 1.9
1.0 ± 0.3 3844.6 ± 130.6 40.9 ± 5.9
0.9 ± 0.2 3487.8 ± 213.2 35.8 ± 2.4
ND 4719.3 ± 391.3 ND
ND 3357.8 ± 443.3 ND
ND 3137.8 ± 210.3 ND
ND - -
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line, chloramphenical and kanamycin (LB-CTCK).
The interaction between the DHFR monomer and the
donated helix within the JR sequence has earlier been
noted from the structures of the bifunctional DHFR-TS
enzymes of C. hominis and P. falciparum [17,33]. An
interaction of the pfDHFR and pfJRTS domains was dem-
onstrated using the E. coli two-hybrid system [27,28,34].
The E. coli reporter strain co-transformed with plasmids
pBT-pfDHFR and pTRG-pfJRTS (with full-length JR se-
quence) can grow on a LB-CTCK agar plate (Figure 6).
The data is in agreement with the complementation results
and results from [3H]-FdUMP binding studies supporting
the importance of JR on the folding of the pfTS domain.
Discussion
The JR represents a junctional region linked between the
DHFR and the TS domain of parasitic protozoa. This re-
gion has been proposed as potential target for drug devel-
opment in many parasitic protozoa. Indeed, this region in
C. hominis from one monomer was reported to make ex-
tension contacts with the DHFR active site of the other
monomer [17]. In P. falciparum, the amino acid residues
Asp283-Asn296 of JR are strongly predicted to be involved
in domain-domain interaction. Unfortunately, the major
portions of JR (Lys232-Asn280) were not seen in the crystal
structure previously reported [33]. Therefore, it remains
unclear whether each DHFR domain of P. falciparum is
linked to the TS domain as seen in C. hominis or there is a
domain swapping assembly. The role of JR was character-
ized with respect to interdomain interaction.
A series of truncated mutants of pfJRTS were constructed
containing varying lengths of JR and their interactions with








Figure 6 Escherichia coli two-hybrid showing interaction between pfD
system (Strategene) was employed for the study of the domain-domain in
coding for pfDHFR was cloned into the bait plasmid pBT, whereas the gen
recombinant plasmids were transformed into the E. coli XL1-blue MRF’ repo
pBT-LDF2 and pTRG-Gal11p provided by the manufacturer. Negative contro
and that on the right is LB- carbenicillin, tetracycline, chloramphenical andTS-deficient E. coli χ2913 and monitoring its growth com-
plementation in minimum media without thymidine sup-
plementation, the study showed that the pfJRTS construct
with the shortest length of JR that could still show growth
complementation in TS-deficient E. coli χ2913 was
pfJRTS△232-276. The specific activity of DHFR determined
for the crude extract of the monofunctional pfDHFR upon
co-expression with pfJRTS△232-276 was 34.2 ± 9.1 nmole/
min/mg, a value which was about half that obtained from
the bifunctional pfDHFR-TS (70.3 ± 3.6 nmole/min/mg),
but was about the same level for all truncated pfJRTS mu-
tants. However, the specificity of TS of this truncated con-
struct was only 1.1 ± 0.1 nmole/min/mg (Table 3), which
is about 29% of the wild-type enzyme (3.7 ± 0.4 nmole/
min/mg). It is noteworthy that the DHFR specific activities
among the co-transformants investigated were compar-
able whereas the TS specific activities were dramatically
reduced upon shortening of the JR sequence. The pfDHFR
and pfJRTS domains could be co-purified by using a
MTX-affinity column, suggesting that the pfDHFR and
pfTS domains interacted with each other because
methotrexate binds only to the pfDHFR domain. For the
co-transformants that lose the pfTS activity including
pfJRTS△232-277 and pfJRTS△232-299, the constructs still
expressed active pfDHFR (Table 3). The expression of cata-
lytically active pfTS upon cotransformation with pfDHFR
plasmid was further confirmed by showing a positive
autoradiogram of covalent complex formed as a result
of [3H]-FdUMP bound to the expressed pfTS from the
pfJRTS△232-276 mutant construct.
These results agree well with the previous studies,
suggesting that the pfDHFR domain is essential for pfTS
to be active [18,35]. However, one interesting piece of






HFR and pfTS domains. Escherichia coli BacterioMatch™ two-hybrid
teraction between P. falciparum DHFR and TS domains. The gene
e for pfJRTS was cloned into the target plasmid pTRG. The two
rter strain. Positive control is E. coli XL1-blue MRF’ co-transformed with
l is E. coli XL1-blue MRF’. Agar plate on the left is LB-kanamycin (LB-K)
kanamycin (LB-CTCK).
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[36] and pfJRTS△232-235 or P. vivax DHFR with
pfJRTS△232-235 could not confer expression of catalyt-
ically active pfTS (data not shown). This finding suggests
that not only minimal length of JR is required but active
pfDHFR domain is also important for the pfTS domain
to be active. Although endogenous DHFR from an E. coli
host exists, the enzyme could not promote the growth of
TS-deficient E. coli. It is possible that amino acids within
the pfDHFR domain are critically necessary to stabilize
the DHFR tertiary structure which could indirectly influ-
ence the correct folding and hence the activity of the
pfTS domain.
The domain-domain interaction of the bifunctional
pfDHFR-TS was further demonstrated using an E. coli
two hybrid system and the results obtained were consist-
ent with other experiments. The pBT-pfDHFR and
pTRG-pfJRTS co-transformant showed interaction and
turned on the AmpR gene, allowing the growth of E. coli
XL1-blue MRF’. The results suggest that the minimal
length of JR which could allow expression of the catalyt-
ically active pfTS was 44 amino acids, approximately half
the full length of JR of the P. falciparum DHFR-TS.
The importance of the length of JR was investigated by
the ability to complement the growth of TS-deficient E.
coli in the absence of thymine of co-transformed plasmids
harbouring the genes for pfDHFR and truncated pfJRTS
compared to plasmid harbouring the gene for the bifunc-
tional pfDHFR-TS. Complementation experiments sup-
port the conclusion that the length of JR sequence is
crucial. The finding that positive complementation was
still observed from the construct of truncated bifunc-
tional pfDHFR-TS△229-274 which possesses two more
amino acid residues than the case of monofunctional
pfJRTS△232-276 could be due to the more complex
structure of the bifunctional protein as compared to the
monofunctional enzymes resulting from the interaction,
or associated with the sensitivity of the complementation
assay system. To further address this discrepancy, a more
sensitive [3H]-FdUMP binding assay method was used to
confirm that pfDHFR-TS△229-276 is the construct with
the shortest length of JR that could still express active
pfTS. The result was in good agreement with the results
from complementation studies using monofunctional
pfJRTS△229-276. The fact that the bifunctional mutant
failed to show complemention in TS-deficient E. coli but
could not detect the activity of pfTS by in vitro enzymatic
assay could be due to the insufficient expression of protein
in combination with the sensitivity of the complemention
method, since a minimum TS activity of ~1-5 nmole/min/
mg is necessary for complementation to be observed in
E. coli χ2913 [37]. It should also be noted that the low ex-
pression observed in the truncated bifunctional pfDHFR-
TS was consistent with a previous mutation study whichproposed that the significant intracellular proteolysis activ-
ity associated with the α-helix structure in this region
could be attributed to the low expression of the mutant
proteins [38].
The present results clearly demonstrated that shortening
the JR sequence in the pfDHFR-TS could affect the activity
of both pfTS and pfDHFR. Contrary to that observed in T.
gondii and C. hominis which have longer JR sequences,
mutations of the JR sequence were reported to affect only
the activity of DHFR but not the activity of TS [39,40].
This and other data support the conclusion that the length
of JR sequence is necessary for the activity of both
pfDHFR and pfTS domains, and hence highlights the im-
portance of the JR sequence in P. falciparum bifunctional
DHFR-TS.
It was not so surprising that the constructs pfJRTS△232-
277 and pfDHFR-TS△229-277 showed no expression of
catalytically active pfTS, despite the fact that the con-
structs contain a sequence that encompasses Asp283-
Asn296, the region previously predicted to form α-helix
and responsible for electrostatic interaction between the
negatively charge residues and positive charge of the
pfDHFR and pfTS from different domains [33]. A number
of possible explanations could be as follows: (i) the length
of JR in the constructs is too short, and this could affect
the formation of a stable helix and consequently disturb
the interaction with pfDHFR and interfere with the
proper formation of pfTS conformation; (ii) too short a
JR sequence could affect the structure which could result
in a steric constraint or functional infringement of one do-
main upon the other; (iii) the existence of translational
autoregulation could block translation of mRNA coding
for bifunctional enzyme from binding to the DHFR domain
of the protein [41]; and, (iv) the mutation could cause ex-
posure of some parts of the enzyme which are sensitive to
proteolysis [38]. Therefore, too short a JR sequence could
neither support interaction between pfDHFR and pfTS do-
mains nor contribute to proper folding of the pfDHFR-TS
bifunctional protein.
Conclusions
The data presented in this study show that: a) the presence
of an active pfDHFR domain and the appropriate length of
JR are critical for pfTS to fold correctly to be catalytically
active; and, b) deletion of JR affects both the activities of
the pfTS and the pfDHFR domain of the bifunctional
pfDHFR-TS. From this study, the JR of P. falciparum has a
unique role which is different from other long linker
parasitic protozoa. The data described here could be use-
ful for the development of compounds that bind to the
JR and interfere with the dimerization of the pfTS
subdomains. These studies could potentially lead to novel
means of development of inhibitors targeting the JR se-
quence of the parasite.
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